Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics ...

Anthem BioScience Ltd. filed its preliminary papers with the Securities and Exchange Board of India on Tuesday to raise Rs ...

with a Buy rating and $72 price target Three clinical programs establish Avidity’s Antibody Oligonucleotide Conjugate platform for future pipeline diversification, the analyst tells investors in ...

Avidity Biosciences Inc is a biotechnology company. The company develops novel Antibody Oligonucleotide Conjugates therapies designed to overcome the current limitations of oligonucleotide ...

(Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced that on December 20 ...

Through this proprietary, versatile and modular approach, Entrada is advancing a robust development portfolio of RNA-, antibody- and enzyme-based programs for the potential treatment of neuromuscular, ...

Additionally, the antibody proved “consistent across subgroups” and appeared well tolerated in both IBD conditions with no safety signals identified, according to the partners. Overall rates ...

Department of Chemistry, University of Oxford, Mansfield Road, Oxford OX1 3TA, U.K. Department of Chemistry, University College London, 20 Gordon Street, London WC1H ...

1 Department of Pharmacy, The First Hospital of Changsha, Changsha, Hunan, China 2 Center of Clinical Pharmacology, Third Xiangya Hospital, Central South University, Changsha, Hunan, China ...

Poly(ADP-ribosyl)ation and Genome Integrity, Laboratoire d’Excellence Medalis, UMR7242, Centre National de la Recherche Scientifique/Université de Strasbourg ...